128-13-2 with low p...

128-13-2 with low price of Ursodiol 128-13-2

128-13-2 with low price of Ursodiol 128-13-2

Min.Order / FOB Price:Get Latest Price

5 Kilogram

Negotiable

  • Min.Order :5 Kilogram
  • Purity: ≥ 99.0%
  • Payment Terms : L/C,T/T

Keywords

128-13-2 with low price Ursodiol 128-13-2 128-13-2 Ursodesoxycholic Acid

Quick Details

  • Appearance:White or almost white crystalline powder, taste bitter, without stink
  • Application:Medical raw materials for hepatobiliary diseases
  • PackAge:25KG/Drum 1KG/Bag
  • ProductionCapacity:8000|Kilogram|Month
  • Storage:Keep in closed vessel & store in room temperature
  • Transportation:

Superiority:

128-13-2 with low price of Ursodiol 128-13-2
 
Ursodeoxycholic acid Basic information
Choleretic drugs Pharmacological effects Chenodeoxycholic acid Drug Interactions Side effects Precautions Determination of the content ursodeoxycholic acid and chenodeoxycholic acid in bear bile by TLCS methodChemical Properties Uses Production method
Product Name: Ursodeoxycholic acid
Synonyms: Adursal;Ursic acid;34784-46-7;rsodeoxycholic acid;Porcine deoxycholic acid;Chenodeoxycholic Acid Impurity 1;(3a,5b,7b)-3,7-Dihydroxycholan-24-oic acid;7BETA-HYDROXYLITHOCHOLIC ACID
CAS: 128-13-2
MF: C24H40O4
MW: 392.57
EINECS: 204-879-3
Product Categories: API;Herb extract;DEPACON;BPC;Bile Acids;Inhibitors;Biochemistry;Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;API's
Mol File: 128-13-2.mol
Ursodeoxycholic acid Structure
 
Ursodeoxycholic acid Chemical Properties
Melting point  203-204 °C(lit.)
alpha  60 º (c=2, EtOH)
Boiling point  437.26°C (rough estimate)
density  0.9985 (rough estimate)
refractive index  60.5 ° (C=2, EtOH)
Fp  9℃
storage temp.  Refrigerator
solubility  ethanol: 50 mg/mL, clear
form  Solution
pka pKa 5.04±0.04(H2O t = 25.0±0.1 I = 0.00)(Approximate)
color  Clear colorless
Water Solubility  practically insoluble
Merck  14,9889
InChIKey RUDATBOHQWOJDD-UZVSRGJWSA-N
CAS DataBase Reference 128-13-2(CAS DataBase Reference)
 
 
As the manufacturer of UDCA, we can provide it with lower price and high quality. We have engaged in UDCA market  for 10 years. We have been constantly innovating in technology, in order to reduce the costs, so that maxmize profits for our customers. Medical raw materials for hepatobiliary diseased. Adding bile acid to secrete bile acid and changing bile composition, reducing cholesterol and cholesterol lipid in bile is beneficial to the gradual dissolution of cholesterol in gallstones.

Details:

Pharmacological effects
Ursodeoxycholic acid, namely 3α, 7 β-dihydroxy bile acid, is the 7β-hydroxy epimer of chenodeoxycholic acid. Because of this small structural difference, the product is hydrophilic. It can reduce the activity of the rate-limiting enzyme in cholesterol synthesis in the liver--β-hydroxyl-β-methylglutaryl coenzyme A (HMG-CoA) reductase, thus inhibiting the cholesterol synthesis. It also forms a stable liquid crystalline suspension with cholesterol, and thus unsaturated the bile cholesterol, thereby promoting the separation and dissolution of cholesterol stone. This product can also inhibit the intestinal absorption of cholesterol. Ursodeoxycholic acid can also antagonize the cytotoxic effects of endogenous hydrophobic bile acids, protecting the liver cell membrane. By reducing the overexpression of the main membrane tissue compatibility antigen MHC-1, it can inhibit the production of interleukin-2,4, tumor necrosis factor and interferon α; and increasing the body's levels of interleukin-10,12; It also directly binds to the glucocorticoid receptor, playing a role in immune regulation. In addition, Ursodeoxycholic acid can also inhibit apoptosis, inhibit inflammation, scavenge free radical and have antioxidant effects. After oral administration, it is absorbed through non-ionic passive diffusion in the jejunum, and through active transport in the ileum. The effect of first-pass is large, 50% to 75% of the orally administrated dose is uptake by liver. It is mainly distributed in the liver, intestines and blood plasma, and has a 96% to 99% plasma protein binding rate. Ursodeoxycholic acid concentration in the bile exhibit dose-dependent increase; upon a dose of 20~30mg/(kg ? d), its concentration in bile is over 60%, reaching the best therapeutic effect. It binds to glycine, taurine in the liver, and is metabolized by intestinal. A small part of metabolite product is excreted from by urine, mostly by the fecal excretion. Biological half-life of oral administration is 3.5 to 5.8 days.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View